
News|Articles|February 13, 2019
Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Author(s)Drew Boxler
Advertisement
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs
Contraindications: None
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
FDA Approves Lumateperone as Adjunct Therapy for Major Depressive Disorder
3
Dementia Increases Risk of COVID-19 Infection, Hospitalization for Older Patients
4
Pharmacists as the Front Line of Vaccine Education and Access
5




















































































































































